Losing a Medicare Advantage plan opens a one-time right to buy Medigap without underwriting.

Doctor consulting with an elderly patient in an office.

The wave of Medicare Advantage plans being dropped for 2027 comes with a piece of good news that often goes unmentioned in the non-renewal letters. When an Advantage plan is discontinued and the member returns to Original Medicare, federal rules open a limited window to buy a Medigap supplement policy without answering a single health question. It is a one-time protection, it is easy to miss, and for anyone with a chronic condition it can be worth thousands of dollars.

The Medigap door a plan termination quietly opens

Medigap, also called Medicare Supplement Insurance, is a private policy that pays costs Original Medicare leaves behind, such as coinsurance, copayments, and deductibles. In most situations, an insurer can look at an applicant’s health history and either charge more or deny the policy outright based on preexisting conditions. That process, called medical underwriting, is what keeps many older people locked into whatever coverage they already have.

A guaranteed-issue right suspends that process. According to Medicare’s guaranteed-issue rules, certain life events force insurers to sell a Medigap policy at their best available rate, cover all preexisting conditions, and skip the health screening entirely. A Medicare Advantage plan being discontinued or pulling out of a member’s service area is one of those triggering events, provided the person moves back to Original Medicare.

Why the no-underwriting window matters most for the sick

The value of this right is concentrated among the people who need it most. A healthy 68-year-old can often pass underwriting and buy a supplement any time. Someone managing heart disease, diabetes, cancer, or another serious condition frequently cannot, because an insurer reviewing that history may decline coverage or price it out of reach. The guaranteed-issue window is the rare moment when health status cannot be used against the applicant.

Losing that window can mean being stuck. A member whose Advantage plan disappears, who misses the guaranteed-issue period, and who later tries to buy Medigap could face underwriting, a denial, or premiums inflated by their diagnoses. Acting inside the window locks in a supplement at the standard rate for the long run, which is why the timing deserves attention the moment a non-renewal notice arrives.


Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.

The 63-day clock that governs everything

The protection is time-limited, and the clock is unforgiving. In a plan-termination situation, the guaranteed-issue right generally runs up to 63 days after the Advantage coverage ends, and Medicare’s guidance notes an application can be submitted as early as 60 days before that coverage stops. That means the practical planning window opens before the plan actually ends and closes about two months after.

Because the window is short and dated to the coverage-end, the plan’s non-renewal letter becomes an essential document. Medicare’s guidance on when to buy Medigap advises keeping proof of the loss of coverage, since the insurer selling the supplement may ask for it to confirm the guaranteed-issue right applies. Filing letters in a drawer and forgetting about them is exactly how a valuable window slips past.

Which Medigap plans a guaranteed-issue right covers

The right does not extend to every supplement on the market. It applies to specific standardized Medigap plans, identified by letter. Medicare’s rules point guaranteed-issue applicants toward plans such as A, B, D, G, K, and L from any insurer that sells Medigap in the state, with the exact menu depending on when a person first became eligible for Medicare. It is a defined list, not an open field, and knowing which letters qualify prevents an applicant from chasing a plan the guarantee does not cover.

State rules can also expand these protections. A handful of states give residents broader or more frequent guaranteed-issue rights than the federal floor, letting people switch supplements without underwriting more often. Checking the state insurance department’s rules alongside the federal baseline can reveal options the standard letter never mentions.

The separate drug-plan deadline that is easy to miss

Securing a Medigap policy solves only part of the coverage puzzle, because Medigap does not include prescription drug coverage. A member returning to Original Medicare from a discontinued Advantage plan also needs a standalone Part D drug plan, and the loss of Advantage drug coverage opens its own special enrollment period to sign up for one. Missing that separate window carries a real cost: a person who goes without creditable drug coverage can face a Part D late-enrollment penalty that is added permanently to future premiums. So the plan-termination letter starts two clocks at once, one for the guaranteed-issue Medigap right and one for Part D enrollment, and both deserve action rather than only the more visible supplement decision.

Turning a plan loss into a coverage upgrade

Framed correctly, a discontinued Advantage plan is not only a disruption; it is an opening. The member can return to Original Medicare, use the guaranteed-issue window to add a Medigap policy without health screening, and pair it with a standalone Part D drug plan, arriving at coverage that many people can no longer qualify for once the window closes. Making that move deliberately, rather than defaulting into whatever replacement Advantage plan is offered, is a decision with lifelong cost consequences.

The core action items are narrow and time-sensitive: keep the plan’s termination letter as proof, note the date coverage ends, and treat the 63-day guaranteed-issue window as a hard deadline rather than a suggestion. For a retiree with health conditions, that single window can be the difference between a supplement that pays reliably for years and no supplement at all.

This article was produced with the assistance of artificial intelligence and reviewed by The Financial Wire editorial team.

More Financial Reading

Leave a Reply

Your email address will not be published. Required fields are marked *